- Clinical oncology company PharmAust (PAA) has secured an extension on its current contract with the Drugs for Neglected Diseases Initiative (DNDI)
- The renewed contract through PAA’s subsidiary, Epichem, expected to generate up to $1.2 million in revenue over the 2021 calendar year
- Epichem will also continue to provide it synthetic and medicinal chemistry services to DNDI’s treatments for neglected diseases
- The contract is a slight decrease on last year’s contract, which anticipated $1.24 million in revenue
- This marks PAA’s 13th year in collaboration with the not-for-profit
- Shares are off 4.55 percent on the back of the announcement trading at 10.5 cents each
PharmAust: Continues research in neglected diseases
